Hepatosplenic T-cell lymphoma in a 47-year-old Crohn's disease patient on thiopurine monotherapy.

about

Hepatosplenic T-cell lymphoma in a 47-year-old Crohn's disease patient on thiopurine monotherapy.

Item

http://www.wikidata.org/entity/Q39615429

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Hepatosplenic T-cell lymphoma ...... ent on thiopurine monotherapy.

@en

Hepatosplenic T-cell lymphoma ...... ent on thiopurine monotherapy.

@nl

type

Item

label

Hepatosplenic T-cell lymphoma ...... ent on thiopurine monotherapy.

@en

Hepatosplenic T-cell lymphoma ...... ent on thiopurine monotherapy.

@nl

prefLabel

Hepatosplenic T-cell lymphoma ...... ent on thiopurine monotherapy.

@en

Hepatosplenic T-cell lymphoma ...... ent on thiopurine monotherapy.

@nl

P1476

Hepatosplenic T-cell lymphoma ...... ent on thiopurine monotherapy.

@en

P2093

D Lucette Schipper

http://www.w3.org/2001/XMLSchema#string

Harm A M Sinnige

http://www.w3.org/2001/XMLSchema#string

Lauranne A A P Derikx

http://www.w3.org/2001/XMLSchema#string

Loes H C Nissen

http://www.w3.org/2001/XMLSchema#string

Maartje M van de Meeberg

http://www.w3.org/2001/XMLSchema#string

Peet Nooijen

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatosplenic gamma-delta T-cell lymphoma.

Do inflammatory bowel disease therapies cause cancer?

The risk of cancer in patients with Crohn's disease.

Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

Use of case reports and the Adverse Event Reporting System in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma.

Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review.

A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.

Hepatosplenic T-cell lymphoma and inflammatory bowel disease.

Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.

T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.

P304

10465-10470

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.3748/WJG.V22.I47.10465

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28058028

http://www.w3.org/2001/XMLSchema#string

P932

5175260

http://www.w3.org/2001/XMLSchema#string